Related Experiment Videos
Antisense oligonucleotide therapy in urology
1Department of Immunology and Cell Biology, Research Center Borstel, Borstel, Germany.
Purpose:
Antisense oligonucleotides are short modified DNA or RNA molecules designed to bind selectively messenger RNA and inhibit synthesis of the encoded protein. In the last 20 years antisense technology has emerged as an exciting and promising strategy, especially for treating cancer. We provide urologists with a contemporary review of relevant background information and outline current treatment strategies and clinical trials of antisense oligonucleotide therapy for urological tumors.
Materials And Methods:
We comprehensively reviewed the literature, including PubMed and recent abstract proceedings from international meetings, on preclinical and clinical studies of antisense oligonucleotide therapy in urology.
Results:
Current preclinical antisense strategies in urological cancer research include the inhibition of proliferation and induction of tumor cell differentiation, reversal of immunosuppression by tumor secreted molecules and induction of apoptosis. The use of phosphorothioate oligonucleotides as antisense agents has shown promising results in various preclinical cancer models. In recent and current clinical trials in patients with urological tumors antisense agents targeted against c-raf kinase, protein kinase C-alpha, protein kinase A and bcl-2 are being evaluated.
Conclusions:
Many compounds have achieved convincing in vitro reduction of target messengerRNA and protein expression. Early clinical trials show safety and mild toxicity at the given doses. Overall the current state of antisense oligonucleotide research described promises a highly productive future for this technology. However, for most medical applications of antisense compounds many obstacles related to nuclease stability, affinity, cellular delivery and specificity remain to be clarified.
Insights
Antisense oligonucleotides show promise for treating urological cancers by inhibiting protein synthesis. Early clinical trials demonstrate safety, but further research is needed to overcome delivery and stability challenges for widespread medical application.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Antisense oligonucleotides are modified DNA/RNA molecules targeting messenger RNA to inhibit protein synthesis.
- Antisense technology has advanced significantly over the past two decades, particularly in cancer treatment strategies.
Purpose of the Study:
- To provide urologists with an updated review of antisense oligonucleotide therapy for urological tumors.
- To outline current treatment strategies and ongoing clinical trials involving antisense agents in urology.
Main Methods:
- A comprehensive literature review of preclinical and clinical studies.
- Searches included PubMed and proceedings from international scientific meetings.
Main Results:
- Preclinical strategies focus on inhibiting proliferation, inducing differentiation and apoptosis, and reversing tumor-induced immunosuppression.
- Phosphorothioate oligonucleotides have shown efficacy in preclinical cancer models.
- Clinical trials are evaluating antisense agents targeting c-raf kinase, protein kinase C-alpha, protein kinase A, and bcl-2 in urological tumors.
Conclusions:
- Antisense compounds effectively reduce target messenger RNA and protein expression in vitro.
- Early clinical trials indicate that antisense agents are safe with mild toxicity at tested doses.
- Significant obstacles including nuclease stability, affinity, cellular delivery, and specificity must be addressed for broader medical application.